American Society of Clinical Oncology
225 Reinekers Lane
2076 articles with American Society of Clinical Oncology
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Informat to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the ASCO
Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform
New data for Sarclisa® (isatuximab-irfc) and Jevtana® (cabazitaxel) in difficult-to-treat cancers reinforce breadth and depth of portfolio
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Promising clinical research supports Xoft brain IORT as a viable treatment option forglioblastoma multiforme that may extend patients’ lives
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference
Two additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be published online
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA® (pembrolizumab) in MSI-H/dMMR Colorectal Cancer
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis--published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
NKMax America Announces Acceptance of Three Abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting
NKMax America announced the acceptance of three abstracts for the upcoming 2020 American Society of Clinical Oncology Annual Meeting.
Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
Lexicon Pharmaceuticals, Inc., announced that data from a poster highlighting XERMELO® will be presented at the American Society for Clinical Oncology 2020 Symposium.
Isofol Medical AB, announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company's proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced colorectal cancer.
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
Innovent Biologics, Inc. announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human BCMA CAR-T co-developed by Innovent and Nanjing IASO Biotherapeutics, was presented by oral presentation and poster at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the 24th Congress of the European Hematological Society and the American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illinois.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO
Innovent Biologics, Inc. announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma by sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, was presented in an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology
Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®
ASCO called rare cancer treatments the "advance of the year" in oncology.
CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.
Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes
Results from cohort with median follow up of 3.2 years presented at 2019 ASCO Annual Meeting